NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free LRMR Stock Alerts $7.32 +0.20 (+2.81%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$7.04▼$7.5850-Day Range$6.33▼$11.5052-Week Range$2.18▼$13.68Volume213,961 shsAverage Volume292,131 shsMarket Capitalization$467.02 millionP/E RatioN/ADividend YieldN/APrice Target$18.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Larimar Therapeutics alerts: Email Address Larimar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside152.7% Upside$18.50 Price TargetShort InterestBearish6.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 13 Articles This WeekInsider TradingAcquiring Shares$37.52 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.24) to ($2.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.58 out of 5 starsMedical Sector1383rd out of 2,771 stocksPharmaceutical Preparations Industry629th out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.11% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 7.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LRMR. Previous Next 1.8 News and Social Media Coverage News SentimentLarimar Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Larimar Therapeutics this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $37,521,993.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.24) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Larimar Therapeutics Stock (NASDAQ:LRMR)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Read More LRMR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LRMR Stock News HeadlinesMay 13 at 5:34 AM | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) to Post FY2026 Earnings of ($2.65) Per Share, William Blair ForecastsMay 10, 2024 | finance.yahoo.comCompanies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating for Larimar Therapeutics Backed by Strong Clinical and Financial OutlookMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Larimar Therapeutics Amid Promising Phase II Data and Strategic OLE Study for FA TreatmentMay 9, 2024 | msn.comLarimar Therapeutics files for $300M mixed shelf offeringMay 9, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024May 9, 2024 | washingtonpost.comLarimar: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comLarimar Therapeutics Reports First Quarter 2024 Operating and Financial ResultsMarch 18, 2024 | msn.com5 Stocks that Analysts Love in March 2024March 16, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 callMarch 16, 2024 | markets.businessinsider.comBuy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug NomlabofuspMarch 14, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023March 14, 2024 | sfgate.comLarimar: Q4 Earnings SnapshotMarch 14, 2024 | benzinga.comRecap: Larimar Therapeutics Q4 EarningsMarch 14, 2024 | finance.yahoo.comLarimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial ResultsMarch 14, 2024 | globenewswire.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp DevelopmentMarch 12, 2024 | markets.businessinsider.comBuy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s AtaxiaMarch 12, 2024 | msn.com3 Best Stocks to Buy Now, 3/12/2024, According to Top AnalystsMarch 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)March 11, 2024 | finance.yahoo.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s AtaxiaMarch 11, 2024 | globenewswire.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's AtaxiaMarch 11, 2024 | msn.comLarimar Therapeutics to Present at Global Biopharma Conference in MiamiMarch 6, 2024 | globenewswire.comLarimar Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceMarch 3, 2024 | bizjournals.comLocal life sciences companies reeled in more than $750M in stock sales in first two months of 2024February 23, 2024 | finance.yahoo.comLRMR Mar 2024 17.500 callSee More Headlines Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/13/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LRMR CUSIPN/A CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees42Year FoundedN/APrice Target and Rating Average Stock Price Target$18.50 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+152.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.69% Return on Assets-32.21% Debt Debt-to-Equity RatioN/A Current Ratio17.99 Quick Ratio17.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book3.94Miscellaneous Outstanding Shares63,800,000Free Float61,059,000Market Cap$467.02 million OptionableOptionable Beta0.96 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 65)CEO, President & Director Comp: $845.63kMr. Michael Celano CPA (Age 65)Secretary & CFO Comp: $562.62kMr. John BermanVice President of Finance & AdministrationMs. Jennifer Spokes JohanssonVice President of Legal & ComplianceDr. Russell G. Clayton Sr. (Age 63)D.O, Chief Medical Officer Dr. Gopi Shankar M.B.A. (Age 53)Ph.D., Chief Development Officer Mr. Francis Michael Conway CPAVP & ControllerMore ExecutivesKey CompetitorsVerve TherapeuticsNASDAQ:VERVAltimmuneNASDAQ:ALTKalVista PharmaceuticalsNASDAQ:KALVTravere TherapeuticsNASDAQ:TVTXOculisNASDAQ:OCSView All CompetitorsInsiders & InstitutionsStemPoint Capital LPSold 42,295 shares on 5/14/2024Ownership: 1.161%HAP Trading LLCBought 40,000 shares on 5/13/2024Ownership: 0.000%Vanguard Group Inc.Bought 912,458 shares on 5/10/2024Ownership: 3.711%Simplex Trading LLCBought 33,000 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Bought 636,185 shares on 4/24/2024Ownership: 0.997%View All Insider TransactionsView All Institutional Transactions LRMR Stock Analysis - Frequently Asked Questions Should I buy or sell Larimar Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares. View LRMR analyst ratings or view top-rated stocks. What is Larimar Therapeutics' stock price target for 2024? 6 analysts have issued 12 month target prices for Larimar Therapeutics' stock. Their LRMR share price targets range from $10.00 to $25.00. On average, they predict the company's stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts. How have LRMR shares performed in 2024? Larimar Therapeutics' stock was trading at $4.55 at the beginning of the year. Since then, LRMR stock has increased by 60.9% and is now trading at $7.32. View the best growth stocks for 2024 here. When is Larimar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our LRMR earnings forecast. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.05. What ETF holds Larimar Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,867 shares of LRMR stock, representing 0.42% of its portfolio. Who are Larimar Therapeutics' major shareholders? Larimar Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.71%), StemPoint Capital LP (1.16%), Assenagon Asset Management S.A. (1.00%), HAP Trading LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LRMR) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportGuard Against the Coming Financial UpheavalPorter & CompanyDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
